STOCK TITAN

Atea Pharmaceuticals Inc - AVIR STOCK NEWS

IMPACT
SENTIMENT
IMPACT
SENTIMENT
AVIR : Nasdaq
conferences
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
Atea Pharmaceuticals Inc

Nasdaq:AVIR

AVIR Rankings

AVIR Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About AVIR

atea pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. the company's lead product candidate is at-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. it also develops at-787 which is under phase 2 clinical for the treatment of hepatitis c virus; at-752 which is under phase 2 clinical trial for the treatment of dengue; and at-889, at-934, and other product candidates for the treatment of respiratory syncytial virus are under phase 2 clinical trials. the company was incorporated in 2012 and is based in boston, massachusetts.